Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-02-14

FDA Approved: AMBRISENTAN — Supplemental Application (Zydus Lifesciences Limited)

View source ↗

Summary

This entry documents a supplemental application for ambrisentan submitted by Zydus Lifesciences Limited to the FDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)